

Transgene Announces Financial Calendar for 2025

Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, **announces its financial reporting dates for 2025:**

March 27, 2025:	2024 Fiscal Year Results
April 24, 2025:	First Quarter 2025 Financial Results
May 15, 2025:	Annual Shareholders' Meeting
September 16, 2025:	First Half 2025 Financial Results
November 4, 2025:	Third Quarter 2025 Financial Results

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the *myvac*[®] platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO[®] viral backbone. With Transgene's *myvac*[®] platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*[®] approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO[®], Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: www.transgene.fr

Follow us on social media: X (formerly Twitter): [@TransgeneSA](https://twitter.com/TransgeneSA) — LinkedIn: [@Transgene](https://www.linkedin.com/company/transgene)

Contacts:

Transgene:

Media:

Caroline Tosch

Corporate Communication Manager
+33 (0)3 68 33 27 38
communication@transgene.fr

Lucie Larguier

Chief Financial Officer

Nadege Bartoli

IR Analyst and Financial Communications Officer
+33 (0)3 88 27 91 03 /00
investorrelations@transgene.fr

Media:

MEDiSTRAVA

Frazer Hall/Sylvie Berrebi

+ 44 (0)203 928 6900
transgene@medistrava.com

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.